Deferoxamine-enhanced fecal losses of aluminum and iron in a patient undergoing continuous ambulatory peritoneal dialysis.
Aluminum-associated osteomalacia and transfusion-induced hemosiderosis developed in an anephric patient receiving long-term maintenance treatment with continuous ambulatory peritoneal dialysis. Intravenous administration of 1.0 g of deferoxamine led to marked increases in the fecal elimination of aluminum and iron. Dialysate removal of these same metals also increased but to a lesser extent. This indicates that the biliary/fecal route of excretion may contribute significantly to deferoxamine-induced losses of aluminum and iron in patients undergoing continuous peritoneal dialysis.
D000328:Adult; D000535:Aluminum / Q000032:analysis / Q000172:deficiency*; D003676:Deferoxamine / Q000009:adverse effects*; D005243:Feces / Q000032:analysis*; D005260:Female; D006486:Hemosiderosis / Q000209:etiology; D006801:Humans; D007501:Iron / Q000032:analysis; D000090463:Iron Deficiencies; D010018:Osteomalacia / Q000209:etiology; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects*; D065227:Transfusion Reaction
D000535:Aluminum; D007501:Iron; D003676:Deferoxamine